SPY334.19+5.46 1.66%
DIA275.90+4.20 1.55%
IXIC11,117.53+203.96 1.87%

Bristol Myers Squibb Announces Phase 3 IDHENTIFY Trial in Patients with Relapsed or Refractory Acute Myeloid Leukemia Did Not Reach The Primary Endpoint

Benzinga · 08/25/2020 11:00